Jin Li
Nantong University(CN)Affiliated Hospital of Nantong University(CN)Fudan University Shanghai Cancer Center(CN)Second People's Hospital of NanTong(CN)First Affiliated Hospital of Xi'an Jiaotong University(CN)University of Virginia(US)
Publications by Year
Research Areas
Colorectal Cancer Treatments and Studies, Gastric Cancer Management and Outcomes, Lung Cancer Treatments and Mutations, Cancer Treatment and Pharmacology, Hepatocellular Carcinoma Treatment and Prognosis
Most-Cited Works
- → Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction(2016)985 cited
- → The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer(2019)852 cited
- → Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial(2015)797 cited
- → Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study(2014)464 cited
- → Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer(2014)267 cited